On Aug. 31, 2020, AstraZeneca announced that the COVID-19 vaccine AZD1222 expanded into U.S. Phase III clinical trial across all adult age groups.

Trial centers across the U.S. planned to recruit up to 30,000 adults aged 18 years or over from diverse racial, ethnic and geographic groups who are healthy or have stable underlying medical conditions, including those living with HIV, and who are at increased risk of infection from the SARS-CoV-2 virus.